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Background
Drug efflux via ATP-binding cassette (ABC) transporters is
one of the main causes for chemoresistance of tumours. P-
glycoprotein (ABCB1) is the main representative of these
efflux pumps, which needs full glycosylation for proper
function. We could previously show that statins have a
double impact on P-glycoprotein [1]. Firstly, statins
inhibit P-glycoprotein which results in higher intracellu-
lar accumulation of chemotherapeutics like doxorubicin.
This could be shown in human neuroblastoma and rhab-
domyosarcoma cells. Secondly, statins reduce the glyco-
sylation level of P-glycoprotein and thereby also lead to
reduced efflux of anthracyclines, which results again in
enhanced apoptosis via the mitochondrial pathway. The
question arises if these effects are also seen in vivo and in
other tumour cells.
Methods and results
In a mouse xenograft model, the liver and rhabdomyosa-
rcoma were analysed for P-glycoprotein levels in the
absence and presence of simvastatin. On protein level P-
glycoprotein was significantly down-regulated in the pres-
ence of pharmacological doses of simvastatin. Prelimi-
nary data confirm compensatory elevation of mRNA for
P-glycoprotein by real time PCR. On cellular level the
compensation of mRNA induction of P-glycoprotein is
seen only after long-time simvastatin exposure of more
than 24 hours. Other ABC-transporters are present in neu-
roblastoma and rhabdomyosarcoma cells and are cur-
rently under investigation, most importantly MRP1
(ABCC1), which allows also doxorubicin export.
Conclusion
Taken together, these data show that pharmacological
doses of simvastatin are sufficient to down regulate P-glyc-
oprotein in normal and tumour tissue in vivo. Thus, inhi-
bition and down-regulation of an ABC transporter by
simvastatin represents a novel mechanism of action
which clearly has clinical implications for cancer therapy.
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